Triplet Therapeutics has developed the SHIELD HD natural history study for Huntington disease (HD), which recently enrolled its first patients. The study will include about 60 HD gene carriers – both pre-manifest and early manifest individuals – and is intended to inform future clinical trials.
If you’re not familiar with Triplet’s therapeutic approach, it’s different from other therapies currently entering the HD clinic, in that it targets a newly discovered set of modifiers for HD instead of the HTT gene. Operating “upstream” means that Triplet may be able to treat the disease very early — an approach that could preserve neuronal function and halt neurodegeneration.
The study is registered at ClinicalTrials.gov (Note: ClinicalTrials.gov lists only the first open site, but there will be more – currently the plan is for 2 sites in Canada.)
You can see the full press release online here.
Status: Currently recruiting.
Study Type: Observational
Location: North York General Hospital, Toronto
Coordinator: Clare Gibbons